Professor Merab Kokaia, one of CombiGene’s scientific founders, has conducted an important study concerning the suppression of epileptic activity via activation of the brain’s Y2 receptors. The study was conducted in human, pharmacoresistant epileptic brain tissue that had been donated in connection with a surgical procedure carried out to inhibit epileptic seizures.
The study clearly demonstrates that, by activating the brain’s Y2 receptors, epileptic activity in pharmacoresistant epileptic brain tissue can be suppressed with NPY. NPY’s mechanism of action is exactly what CombiGene intends to achieve with the candidate drug, CG01. The results therefore provide a very promising basis for testing the treatment in clinical studies.
The results from the study is available here:
https://www.nature.com/articles/s41598-019-56062-1#citeas